New test identifies cancer patients benefit from 10 p-A-day diabetes drug

Current article ratings:
Patients / public:5 (3 votes)healthcare Prof:5 (2 votes)
Scientists have developed a new test to identify patients with aggressive breast cancer who drug diabetes could benefit from a 10-p-a-days.

You used a new method on the basis of the food cancer, the cells food predictions, which patients had a poor prognosis. Exciting, they suggest that these patients by metformin, which show great potential as a cancer treatment drug could benefit a cheap and secure diabetes, is.

The results are from the breakthrough breast cancer Department at the University of Manchester and Thomas Jefferson University in the United States and are now published in the journal of cell cycle.

Professor Michael Lisanti, of the breakthrough breast cancer Department at the University of Manchester, said: "we have shown, that the saying goes,"You are what you eat"applies to cancer." Consume the food cancer cells is crucial how well a patient does and what treatment they need.

"When cancer cells take energy-rich food throughout, a tumor more aggressive and more difficult to handle." However patients could benefit from metformin, which cuts off the fuel supply. "There is more to do, but this test could be an important new way of tailoring treatment to a patient needs, on a variety of cancers."

Professor Lisanti team first saw cells in the laboratory and she fed high energy food, known as lactate and ketones. They found the genes expressed brought based on this fuel supply, and developed a gene signature on this basis.

Then you looked at 219 patients with breast cancer and the cancer cells to ketones and lactate fed studied. This food is healthy cells nearby. They found patients with cancer who consumed high ketones and lactate were more likely to have to spread their disease return, for it to other organs and die. The test combines the gene signature ketone and lactate with the food supply. This could show which patients with a poor prognosis - with the same patients may benefit metformin should have.

Professor Anthony Howell, Director of the breakthrough breast cancer Department in Manchester, said: "we have important new insights in how crabs feed discovered." It is a step in the direction of each patients get the right treatment for you – we call personalized medicine. We are currently reviewing a new way to separate patients on the basis that responds well to the treatments we have, and who might need something else.

"It is particularly encouraging that some of these treatments may already be in the doctor drug control cabinet and cheap to prescribe." "We have some way to go, but we hope that drugs like metformin will save lives from breast cancer in the next few years."

Source code
Breakthrough breast cancer